Quarterly report pursuant to Section 13 or 15(d)

STATEMENTS OF CASH FLOWS

v3.20.1
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (14,911) $ (7,204)
Reconciliation of net loss to net cash used in operating activities    
Depreciation and amortization 47 37
Stock-based compensation expense 776 682
Due to Parent under asset contribution agreement   500
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (1,838) (1,292)
Accounts payable, accrued expenses and other 3,769 1,607
Net cash used in operating activities (12,157) (5,670)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of equipment and leasehold improvements (16) (600)
Net cash used in investing activities (16) (600)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock, net of issuance costs 68,811  
Purchase and cancellation of shares from BioXcel Corporation (9,024)  
Exercise of options 39 1
Net cash provided by financing activities 59,826 1
Net (decrease) increase in cash and cash equivalents 47,653 (6,269)
Cash and cash equivalents, beginning of the period 32,426 42,565
Cash and cash equivalents, end of the period 80,079 36,296
Supplemental cash flow information:    
Interest paid $ 3 $ 8